DelveInsight’s “Post-Traumatic Stress Disorder (PTSD) – Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Post-Traumatic Stress Disorder, historical and forecasted epidemiology, as well as the PTSD market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
To know in detail about the Post-Traumatic Stress Disorder market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Post-Traumatic Stress Disorder Market Forecast
Some of the Key Facts of the Post-Traumatic Stress Disorder Market Report:
- The PTSD market size across the 7MM was valued at approximately USD 1,867 million in 2025.
- The PTSD market in the United States accounted for the highest market share among the 7MM, approximately 90% of the total PTSD market size.
- The United States accounted for more than USD 1,500 million in 2024.
- In 2024, the diagnosed prevalent cases of PTSD were approximately 5,400,000 cases in the 7MM, with the US recording approximately 4,000,000 diagnosed cases.
- The prevalent cases of PTSD by age are highest in the 45–59 age group, followed closely by individuals aged 30–44 years in the United States. In the US, females were more affected by PTSD than males in 2024.
- Key PTSD Companies: Viatris, Apotex, Otsuka Pharmaceuticals, Bionomics, and others.
- Key PTSD Therapies: REXULTI + ZOLOFT (brexpiprazole + sertraline), BNC210, Lofexidine, BI 1358894, and others.
- The PTSD market is expected to grow at a CAGR of approximately 12.2% during the forecast period 2025–2034, reaching USD 5,256 million by 2034, driven by rising prevalence, expanding pipeline, and increasing awareness across diverse populations.
Post-Traumatic Stress Disorder Overview
Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, or rape, or who have been threatened with death, sexual violence, or serious injury. People with PTSD have intense, disturbing thoughts and feelings related to their experience that last long after the traumatic event has ended. They may relive the event through flashbacks or nightmares and may feel sadness, fear, or anger, or feel detached or estranged from others. Symptoms are generally grouped into four types: intrusive memories, avoidance, negative changes in thinking and mood, and changes in physical and emotional reactions.
Get a Free sample for the Post-Traumatic Stress Disorder Market Forecast, Size & Share Analysis Report
Post-Traumatic Stress Disorder Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Post-Traumatic Stress Disorder Epidemiology Segmentation:
The PTSD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total 12-Month Prevalent Cases of Post-Traumatic Stress Disorder
- Total Diagnosed Prevalent Cases of Post-Traumatic Stress Disorder
- Gender-Specific Cases of Post-Traumatic Stress Disorder
- Age-Specific Cases of Post-Traumatic Stress Disorder
- Severity-Specific Cases of Post-Traumatic Stress Disorder
- Total Treated Cases of Post-Traumatic Stress Disorder
Download the report to understand which factors are driving Post-Traumatic Stress Disorder epidemiology trends @ Post-Traumatic Stress Disorder Epidemiology Forecast
Post-Traumatic Stress Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post-Traumatic Stress Disorder market or expected to get launched during the study period. The analysis covers PTSD market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Post-Traumatic Stress Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Post-Traumatic Stress Disorder Therapies and Key Companies
- REXULTI + ZOLOFT (brexpiprazole + sertraline): Otsuka Pharmaceuticals
- BNC210: Bionomics Limited
- Lofexidine: US WorldMeds
- BI 1358894: Boehringer Ingelheim
Discover more about therapies set to grab major Post-Traumatic Stress Disorder market share @ Post-Traumatic Stress Disorder Treatment Landscape
Post-Traumatic Stress Disorder Market Drivers
- Rising PTSD prevalence is driven by increasing awareness, improved diagnostic tools, and recognition of PTSD across diverse populations, with approximately 4,000,000 cases diagnosed in the United States alone in 2024.
- A robust treatment pipeline with ongoing clinical trials targeting unmet needs, including investigational therapies such as brexpiprazole + sertraline, BNC210, and psilocybin, showing promise for improved efficacy and personalized treatment options.
- Positive Phase 2 results for BNC210 published in NEJM Evidence in December 2024, reinforcing confidence in novel mechanisms of action for PTSD management.
- Advancing regulatory activity, including the FDA’s convening of a Psychopharmacologic Drugs Advisory Committee (PDAC) meeting to discuss the sNDA for brexpiprazole in combination with sertraline for treating PTSD in adults.
Post-Traumatic Stress Disorder Market Barriers
- Limited number of FDA-approved disease-specific pharmacological therapies, with only sertraline (ZOLOFT) and paroxetine (PAXIL) currently approved, leaving a significant unmet need for new treatment options.
- High rate of underdiagnosis and treatment gaps, with total treated cases in the US estimated at approximately 1,800,000 in 2024 against a diagnosed pool of approximately 4,000,000.
- Stigma associated with mental health diagnoses, which can deter patients from seeking timely diagnosis and treatment.
- Reimbursement and market access challenges, particularly for innovative and high-cost emerging therapies, which may restrict patient uptake across certain regions.
Scope of the Post-Traumatic Stress Disorder Market Report
- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key PTSD Companies: Viatris, Apotex, Otsuka Pharmaceuticals, Bionomics, and others
- Key PTSD Therapies: brexpiprazole + sertraline, BNC210, Lofexidine, BI 1358894, and others
- PTSD Therapeutic Assessment: PTSD current marketed and PTSD emerging therapies
- PTSD Market Dynamics: PTSD market drivers and PTSD market barriers
- Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis, Market entry strategies
- PTSD Unmet Needs, KOL’s views, Analyst’s views, PTSD Market Access and Reimbursement
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Contact Us
Kanishk
